Cargando…
SMARCA4 loss irrelevant for ARID1A mutated ovarian clear cell carcinoma: A case report
Clear cell carcinomas are rare and relatively chemo-insensitive ovarian cancers with a characteristic molecular pathogenesis. Alterations in ARID1A, a component of the multiprotein chromatin remodeling complex SWI/SNF, are likely early events in the development of ovarian clear cancers arising from...
Autores principales: | Wagner, Samantha Kay, Moon, Ashley S., Howitt, Brooke E., Renz, Malte |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685047/ https://www.ncbi.nlm.nih.gov/pubmed/38033359 http://dx.doi.org/10.1016/j.gore.2023.101305 |
Ejemplares similares
-
Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
por: McNamara, Blair, et al.
Publicado: (2023) -
Clinicopathological Significance of Loss of ARID1A Immunoreactivity in Ovarian Clear Cell Carcinoma
por: Maeda, Daichi, et al.
Publicado: (2010) -
Analysis of SMARCA4 and SMARCA2 Loss in Lung Sarcomatoid Carcinomas
por: Urer, Halide Nur, et al.
Publicado: (2023) -
Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type
por: Jelinic, Petar, et al.
Publicado: (2016) -
The evolution of Big Data in neuroscience and neurology
por: Dipietro, Laura, et al.
Publicado: (2023)